Hughes H P, Campos M, Potter A A, Babiuk L A
Veterinary Infectious Disease Organization, Saskatoon, Saskatchewan, Canada.
Infect Immun. 1992 Feb;60(2):565-70. doi: 10.1128/iai.60.2.565-570.1992.
A chimeric recombinant protein composed of the lktA gene product from Pasteurella haemolytica fused to bovine interleukin-2 (IL-2) was made. The LKT-IL-2 chimera was compared with recombinant bovine IL-2 with regard to the ability to induce proliferative responses and LAK cell activity in bovine peripheral blood mononuclear cells in vitro. In both instances, chimerization had no effect on IL-2 activity. Similarly, the LKT component was unaffected in its ability to induce an effective immune response after immunization. The adjuvant properties of IL-2 have been established in a number of models, and this effect was tested by using the chimera. A multiple-injection protocol of LKT-IL-2 was compared with single-dose administration of LKT. The results obtained indicate that while there was no increase in specific antibody production, the IL-2 component of the chimera may be able to affect antigen-specific proliferation, as assessed by limiting-dilution analysis. Use of cytokine-antigen chimeras may provide a valuable antigen-adjuvant formulation that is simple to produce and purify and thus have economic advantages over conventional preparations. Furthermore, chimerization will also ensure that the adjuvant acts at the same site as the antigen, thus optimizing immunostimulatory activity.
构建了一种嵌合重组蛋白,该蛋白由溶血巴斯德氏菌的lktA基因产物与牛白细胞介素-2(IL-2)融合而成。将LKT-IL-2嵌合体与重组牛IL-2在体外诱导牛外周血单个核细胞增殖反应和LAK细胞活性的能力方面进行了比较。在这两种情况下,嵌合化对IL-2活性均无影响。同样,LKT成分在免疫后诱导有效免疫反应的能力也未受影响。IL-2的佐剂特性已在多个模型中得到证实,并且使用该嵌合体对此效应进行了测试。将LKT-IL-2的多次注射方案与LKT的单剂量给药进行了比较。获得的结果表明,虽然特异性抗体产生没有增加,但通过有限稀释分析评估,嵌合体的IL-2成分可能能够影响抗原特异性增殖。使用细胞因子-抗原嵌合体可能会提供一种有价值的抗原-佐剂制剂,其生产和纯化简单,因此比传统制剂具有经济优势。此外,嵌合化还将确保佐剂与抗原在同一部位起作用,从而优化免疫刺激活性。